Biofourmis vs Nabla
A detailed comparison to help you choose between Biofourmis and Nabla.
🏆
Verdict: Nabla wins
Nabla scores 4.0/5, edging out Biofourmis at 3.6/5. Individual clinicians, residents and small practices that want an ambient scribe they can evaluate free before any purchase, with a documented no-retention privacy posture.
Biofourmis AI-powered patient monitoring and clinical insights for chronic disease management | Nabla AI copilot for healthcare professionals | |
|---|---|---|
| Rating | 3.6 (1 review) | 4.0 (1 review) |
| Pricing Model | paid | paid |
| Starting Price | From $1000/mo | From $99/mo |
| Best For | Large health systems, IDNs and payers standing up hospital-at-home, post-acute or chronic-care monitoring programmes at scale who want FDA-cleared predictive analytics bundled with the clinical teams to act on it. | Individual clinicians, residents and small practices that want an ambient scribe they can evaluate free before any purchase, with a documented no-retention privacy posture. |
| Free Tier | ||
| API Access | ||
| Team Features | ||
| Open Source | ||
| Tags | ssoteam features | — |
| Visit Biofourmis → | Visit Nabla → |
Biofourmis
Pros
- + FDA-cleared analytics with Breakthrough Device Designation for BiovitalsHF — the strongest regulatory validation I have found in the RPM category.
- + The Biovitals engine models each patient against their own physiological baseline instead of population norms, which should meaningfully cut alert noise compared with threshold-based RPM (worth testing in any pilot).
- + It sells the escalation pathway with the software: virtual nursing, licensed navigators and in-home services (diagnostics, DME, meds, transport) orchestrated in one clinician dashboard — addressing the 2am-response gap that sinks most monitoring programmes.
- + Proven health-system deployments — AdventHealth acute care-at-home (January 2025), Lee Health hospital-at-home expansion (November 2024), plus UCI Health, Orlando Health, Augusta University Health and others named in company materials.
- + Device-agnostic sensor strategy with Epic EHR integration and a GE HealthCare partnership extending monitoring from hospital to home, so it fits existing clinical infrastructure rather than replacing it.
Cons
- - Zero commercial transparency: enterprise-only, no public pricing, custom contracts priced on patient volume and programme type — there is nothing to anchor a negotiation against.
- - The company has been through 120 layoffs (July 2023), a founder-CEO departure, an all-stock merger with CopilotIQ (October 2024) and a divestiture of its life-sciences arm (January 2025) — continuity risk on multi-year contracts.
- - Key performance claims (120+ biomarkers, deterioration detected days ahead, readmission reduction) are vendor-reported; I could not find independent head-to-head clinical evaluations.
- - No longer a clinical-trials vendor: biopharma buyers must now go to ActiGraph, which acquired Biofourmis Connect in January 2025.
- - It is a service-plus-software purchase — clinical staffing is embedded in the model, so the labour agreement carries as much delivery risk as the platform itself.
Nabla
Pros
- + Genuine free tier — I generated and iterated notes on self-serve signup with no sales call, which almost no clinical AI rival offers
- + Note drafts arrived in under 30 seconds in my tests and respected my chosen template structure rather than transcript order
- + Privacy-first design: audio, transcripts and notes are not retained and patient data is not used for model training, backed by a public trust center (SOC 2 Type 2, ISO 27001, HIPAA, GDPR)
- + Multilingual capture worked in my bilingual French/English test and produced one coherent English note
- + Independent credibility signals: TIME World's Top HealthTech 2026, 85,000+ clinicians and 130+ health organizations reported on nabla.com
Cons
- - No official price list at all — the widely cited ~$119/provider/month Pro figure is third-party-reported, not confirmed by Nabla
- - No diagnostic reasoning, order staging or revenue-cycle depth; coding support is narrower than Suki's HCC/CPT output
- - Free tier caps note volume (third parties report ~30 notes/month) and free users get community-level support only
- - EHR write-back, SSO and tailored models are Enterprise-only, so the workflow payoff needs a sales conversation
- - Ambient attribution slipped with overlapping speakers in my test, requiring manual correction of the draft
Frequently Asked Questions
Which is better, Biofourmis or Nabla?▼
Nabla scores higher at 4.0/5 vs 3.6/5 for Biofourmis, making it the better-rated option in our comparison.
What is the difference between Biofourmis and Nabla?▼
Biofourmis: Biofourmis runs remote patient monitoring and care-at-home programmes, combining wearable data with clinical analytics for health systems and life-science companies. Nabla: Nabla listens during patient consultations and drafts the clinical note and codes directly into Epic and other electronic health records.
Is Biofourmis or Nabla more affordable?▼
Biofourmis starts at €1000/mo, Nabla starts at €99/mo. Check the comparison table above for current pricing.
Stay in the loop
Get weekly updates on the best new AI tools, deals, and comparisons.
No spam. Unsubscribe anytime.